Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: Insights from cardiac magnetic resonance imaging

International Journal of Cardiovascular Imaging

Volumn 28, Issue 4, 2012, Pages 763-772

  Park, Jeong Rang ^a,c   Choi, Jin Oh ^a   Han, Hye Jin ^a   Chang, Sung A ^a   Park, Sung Ji ^a   Lee, Sang Chol ^a   Choe, Yeon Hyeon ^a   Park, Seung Woo ^a   Oh, Jae K ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Mayo Clinic   (United States)

^c Gyeongsang National University   (South Korea)

Author keywords

Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; N terminal pro B type natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; GADOLINIUM PENTETATE; RENIN INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL WALL; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; ATRIAL FUNCTION, LEFT; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84865529790     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-011-9876-4     Document Type: Article

References (24)

1. Hasegawa K, Fujiwara H, Doyama K et al (1993) Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88:372-380 (Pubitemid 23228035)
2. Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C (2005) Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 150:1228-1232 (Pubitemid 41773527)
3. Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC (2004) Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23:1557-1582 (Pubitemid 40203759)
4. Maron BJ, Tholakanahalli VN, Zenovich AG et al (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984-989 (Pubitemid 38282851)
5. Nishigaki K, Tomita M, Kagawa K et al (1996) Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 28:1234-1242 (Pubitemid 26377000)
6. Panou FK, Kotseroglou VK, Lakoumentas JA et al (2006) Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Hellenic J Cardiol 47:344-351 (Pubitemid 47621120)
7. Kim SW, Park SW, Lim SH et al (2006) Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol 29:155-160
8. Caselli S, Pelliccia A, Maron M et al (2008) Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol 102:616-620
9. Magga J, Sipola P, Vuolteenaho O et al (2008) Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. Am J Cardiol 101:1185-1190
10. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-1320 (Pubitemid 34250486)
11. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785-789
12. Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358-367
13. Thaman R, Esteban MT, Barnes S et al (2006) Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98:515-519 (Pubitemid 44162879)
14. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y (2006) Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 98: 1504-1506 (Pubitemid 44779482)
15. Mizuno Y, Yoshimura M, Harada E et al. (2000) Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86:1036-1040, A11
16. Murakami Y, Shimada T, Inoue S et al (2002) New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18:1294-1300 (Pubitemid 36215780)
17. Shim CY, Ha JW, Choi EY et al (2009) Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy. Korean Circ J 39:519-524
18. Maron BJ, Spirito P (1998) Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81:1339-1344 (Pubitemid 28268673)
19. Binder J, Ommen SR, Chen HH, Ackerman MJ, Tajik AJ, Jaffe AS (2007) Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 15(100):712-714 (Pubitemid 47223150)
20. Sakamoto T (2001) Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview. J Cardiol 37(Suppl 1):161-178
21. Das SR, Drazner MH, Dries DL et al (2005) Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112:2163-2168 (Pubitemid 41475811)
22. Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47:85-90 (Pubitemid 43005169)
23. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976-982 (Pubitemid 34994995)
24. Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29-34 (Pubitemid 34671198)